HSBC raises Bristol-Myers Squibb price target to $65
HSBC increased its price target on Bristol-Myers Squibb (BMY) to $65, citing a Phase II update in the company’s experimental cell therapy that met a primary endpoint.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.